CURE Pharmaceutical Announces US Patent Allowances

OXNARD, Calif., March 13, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”) or (the “company”), a leading disruptive drug delivery technology company serving the pharmaceutical, biotech, veterinarian, medical foods markets, and new chemical entities (NCEs), today announces the U.S. Patent and Trademark Office (USPTO) has granted Patent #9,561,182 covering the method of manufacture and method of use of the company’s proprietary oral thin film technology for the administration of medicaments in order to treat animals.  The demand for US animal health products is more than $12 billion per year.

“This patent adds an important aspect to our intellectual property portfolio, as it now ensures many of the same protections we enjoy in human products to animal products, which can be used in a variety of contexts, from households with pets to farms,” said Rob Davidson, CEO of CURE Pharmaceutical.  “This is also further validation of our unique approach to the development of oral thin film and our proprietary CureFilm technology.”

The patent allowance covers the company’s proprietary CureFilm™ technology delivering a variety of medicinal products specifically oriented toward and flavored for a wide variety of animals including house pets (cats, dogs, guinea pigs, mice, hamsters, ferrets, rabbits reptiles), certain livestock (sheep, cows, horses, goats, swine) and apes/primates.

“This action also represents an important expansion in the methodology veterinarians may have moving forward to deliver important medicines to the animals for whom they care,” added Greg Strathe, DVM, CURE Pharmaceutical advisory board member, and co-owner SAHO, Small Animal Hospital of Owasso, Okla.  “The expansion of our ability to improve care continues to be a priority for those in veterinary medicine, and I believe that this approach is a true innovation.”

About CURE Pharmaceutical Headquartered in Oxnard, CA, CURE Pharmaceutical is a fully integrated specialty pharmaceutical/bioscience company with disruptive proprietary drug delivery technologies for a broad range of molecules that it develops and manufactures in its state of the art cGMP facility.  CURE leverages novel drug delivery technologies to develop and commercialize new applications of proven therapeutics. Cure partners with pharmaceutical and biotech companies looking for new methods to deliver their proprietary molecules.   The technology enables differentiation within large therapeutic categories and potentially improves patient compliance while widening the therapeutic index.  CURE Pharmaceutical is traded under the symbol CURR.  For more information about CURE Pharmaceutical, please visit its website at www.curepharmaceutical.com . 

Forward-looking statements This press release contains forward-looking statements, which are subject to a number of risks and uncertainties. All statements, other than statements of fact, including those statements with respect to the Company's business development, are forward-looking statements. Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements.

Contact: Jules Abraham JQA Partners, Inc. 917-885-7378 jabraham@jqapartners.com